Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Vasodialators Methods-of-inducing-analgesia-or-anesthesia-and-treating-or-preventing-ischemic-injury-of-tissues-in-general

 Floating sustained release therapeutic compositions
OF THE INVENTION According to the present invention, therapeutic dosage forms have now been ...


 Solid oral dosage forms of ifosfamide
OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 I...


 [(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt ...


 Methods for treating dermatitis using descarboethoxyloratadine
OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human ...


 Fat emulsions containing isocarbacyclin
What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable ...


 Dermal pharmaceutical preparations
OF THE INVENTION The support which can be used in the present invention functions to retain a ...


 Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the ...


 2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use
We claim: 1. A compound of the formula I ##STR11## in which n denotes 1, 2, 3 or 4, R denotes (C....


 N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof
We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (...


 Bicyclic amino acids as intermediates in the preparation of tricyclic amino acids and processes for their preparation
We claim: 1. A compound of the formula III ##STR19## in which A denotes --CH.dbd.CH-- or --CH.sub.2 ...


 Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general

Details
Inventors: Miyamoto, Tadaomi; Miyamoto, Koho;
Assignee: Meddiss, Incorporated (Fukuoka, JP)
Primary Examiner: Jones; Dwayne C.
Assistant Examiner:
Attorney, Agent or Firm: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

The invention relates to methods for inducing analgesia (or even anesthesia) and for prevention or amelioration of damage caused by ischemic or traumatic injury of tissues in general, but especially neural, for the central nervous system being the most vulnerable of all tissues, by the systemic administration of a therapeutically effective amount of primarily taurine, and secondarily homotaurine and/or methionine for a sufficient period of time (several hours to a few days, depending on the severity of the injury, and timing when therapy is initiated from the time of injury) to allow recovery from the original insult or from phenomena that follow the initial injury.

DETAILED DESCRIPTION This invention is therefore aimed at solving the above-mentioned shortcoming of adenosinergic approaches, while obtaining either analgesic (anesthetic) or protective effects, thus providing similar or even greater beneficial effects than adenosinergic approaches without the troublesome hypotension.
Exogenous purinergic compounds delivered directly in the brain tissue via microdyalisis probes (thus avoiding hypotension that plagues systemic administration) (a well known technique for those skilled in the art of drug delivery for pharmacological studies and analysis of interstitial fluid levels of various substances including aminoacids) induces the release of a number of inhibitory aminoacids but especially taurine into the CNS interstitial space.
Therefore the logical conclusion is that some of the beneficial effects so far ascribed to adenosine could be actually due to this taurine, which is known to have important inhibitory, anticalcic and antioxidant activities, for which it has been described as the natural protective substance (Huxtable, 1980; Wright, 1986).
Ischemic injury involves Ca.
sup.
++ overload of cells and subsequent oxidation of lipid membrane and cytoskeleton structures; this phenomenon is particularly conspicuous in the excitable CNS tissue (Wieloch, 1982).
The anticalcic and antioxidant effects of taurine have been shown in the retina and various neural preparations (cultures, slices, synaptosomes) as well as in cardiac tissue, thus establishing the grounds for extending the protective effects to tissues other than the CNS as well, for the treatment or prevention of ischemic injury of a variety of organs.
For metabolic reasons (Lloyd, 1988; Schrader, 1991) the combined use of taurine with homotaurine or with methionine should result in mutually potentiating effects.
The simultaneous use of small amounts of purinergic compounds (not enough to produce significant hypotension) and taurine alone or taurine+homotaurine and/or with methionine are likewise supplementary and are expected to further potentiate mutually their analgesic and/or anesthetic, and protective effects



Related patents
  Oil composition
What is claimed is: 1. An oil composition, comprising about 0.1 to 59.8% by weight of a triglyceride, about 40 to 99.7% by weight of a diglyceride, about 0.1 to 10% by ...
  Blocking agents of EDRF effect or formation for the treatment of shock
We claim: 1. A therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein an effective amount of a ...
  Use of polyamines as ionic-channel regulating agents
OF THE PREFERRED EMBODIMENTS The disclosure of any and all cited documents including literature and patent application is incorporated by reference in its entirety. It ...
  Inhibitor of ceramidase
It is a general object of the invention to provide a method of selecting compounds that cause intracellular accumulation of ceramide. It is a specific object of the ...
  Treatment of bone disorders with adrenomedullin
OF THE INVENTION It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following ...
  99MTC(III) myocardial imaging agents and method of use
OF THE INVENTION The technetium compounds of the present invention which have been found most useful as myocardial imaging agents in humans comprise hexadentate ...
  1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents
OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following reaction scheme. ##STR6## Referring to the above reaction scheme, compounds ...
  Vaginal sponge delivery system
These and other objects of the invention are achieved in a product which broadly comprises (a) a sealed, air-tight package, enclosing therein (b) a sponge impregnated ...
  Controlled release formulation
What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation in the form of an uncoated tablet from which upon ingestion ...
  Formulations providing three distinct releases
We claim: 1. A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which ...

0.004

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved